Abstract
Previous studies established the efficacy of oncedaily tadalafil for men with erectile dysfunction. However, no trial has focused on the effects of such treatment on men without previous experience using oral phosphodiesterase type 5 inhibitors. Patients were randomized (2:1) to once-daily tadalafil 5mg (with possible down-titration to 2.5mg; n=146) or placebo (n=69) for 12 weeks. Among 215 patients (mean age, 52 years), once-daily tadalafil treatment resulted in 61.7% of study participants reporting their ability to achieve and maintain erections as being much better or very much better (vs 21.7% on placebo; P
Original language | English |
---|---|
Pages (from-to) | 1305-1322 |
Number of pages | 18 |
Journal | Journal of Andrology |
Volume | 33 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2012 |
Keywords
- Drug therapy
- Efficacy
- Endothelium
- Erection
- Morning
- Nocturnal
- Peripheral arterial tonometry
- Phosphodiesterases
- Psychosocial assessments
- Tolerability
- Treatment outcome
ASJC Scopus subject areas
- Urology
- Reproductive Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology